A device that analyzes blood levels of prostate-specific antigen (PSA) is one of the first doctor’s-office uses of microfluidics–technology that can manipulate fluids on a chip at microscopic scales. When a cartridge bearing a blood sample is inserted into the tabletop device, an accurate reading can be completed in 15 minutes, helping monitor the health of patients with prostate cancer. The procedure used now involves sending a sample to a lab for analysis, which often takes a day or two. The device received European approval in June.
Credit: Christopher Harting
Product: Claros DX 1
Cost: To be announced in late 2010
Availability: Late 2010 in selected European markets
Subscribe to Continue Reading
Uh oh–you've read all five of your free articles for this month.
Insider Online Only
$19.95/yr US PRICE
Personalized Cancer Vaccine Prevents Leukemia Relapse in Patients
A majority of patients in a small clinical trial have been in remission from a deadly type of cancer for more than four years.
Biotech Trial of the Century Could Determine Who Owns CRISPR
Attorneys in a dispute over CRISPR gene-editing make their case to patent judges.
Shoddy Medication? Search Engines May Already Know
People voice concerns about drugs via search queries—and that data that can predict when one might be recalled.